KR20070079390A - Cosmetic composition for skin whitening - Google Patents
Cosmetic composition for skin whitening Download PDFInfo
- Publication number
- KR20070079390A KR20070079390A KR1020060010013A KR20060010013A KR20070079390A KR 20070079390 A KR20070079390 A KR 20070079390A KR 1020060010013 A KR1020060010013 A KR 1020060010013A KR 20060010013 A KR20060010013 A KR 20060010013A KR 20070079390 A KR20070079390 A KR 20070079390A
- Authority
- KR
- South Korea
- Prior art keywords
- skin
- extract
- whitening
- tocopherol
- beta
- Prior art date
Links
- 230000002087 whitening effect Effects 0.000 title claims abstract description 41
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 239000002537 cosmetic Substances 0.000 title claims abstract description 24
- 239000000284 extract Substances 0.000 claims abstract description 41
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims abstract description 27
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims abstract description 24
- 235000013734 beta-carotene Nutrition 0.000 claims abstract description 24
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims abstract description 24
- 239000011648 beta-carotene Substances 0.000 claims abstract description 24
- 229960002747 betacarotene Drugs 0.000 claims abstract description 24
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims abstract description 24
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims abstract description 24
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229930003799 tocopherol Natural products 0.000 claims abstract description 18
- 235000010384 tocopherol Nutrition 0.000 claims abstract description 18
- 239000011732 tocopherol Substances 0.000 claims abstract description 18
- 229960001295 tocopherol Drugs 0.000 claims abstract description 18
- 235000006770 Malva sylvestris Nutrition 0.000 claims abstract description 5
- 240000002129 Malva sylvestris Species 0.000 claims abstract description 5
- 244000072254 Primula veris Species 0.000 claims abstract description 5
- 235000002343 Primula veris Nutrition 0.000 claims abstract description 5
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 26
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 26
- 229940110767 coenzyme Q10 Drugs 0.000 claims description 23
- 241000245063 Primula Species 0.000 claims description 18
- 235000000497 Primula Nutrition 0.000 claims description 16
- 240000000982 Malva neglecta Species 0.000 claims description 3
- 235000000060 Malva neglecta Nutrition 0.000 claims description 3
- 235000016311 Primula vulgaris Nutrition 0.000 claims description 2
- 208000012641 Pigmentation disease Diseases 0.000 abstract description 17
- 230000019612 pigmentation Effects 0.000 abstract description 11
- 230000002401 inhibitory effect Effects 0.000 abstract description 7
- 208000003351 Melanosis Diseases 0.000 abstract description 4
- 230000002159 abnormal effect Effects 0.000 abstract description 2
- 206010008570 Chloasma Diseases 0.000 abstract 1
- 206010064503 Excessive skin Diseases 0.000 abstract 1
- 206010039897 Sedation Diseases 0.000 abstract 1
- 230000003061 melanogenesis Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 36
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 24
- 230000000694 effects Effects 0.000 description 19
- 230000000052 comparative effect Effects 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 10
- 239000000049 pigment Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 238000009472 formulation Methods 0.000 description 7
- 229940066595 beta tocopherol Drugs 0.000 description 6
- WGVKWNUPNGFDFJ-DQCZWYHMSA-N beta-Tocopherol Natural products OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C WGVKWNUPNGFDFJ-DQCZWYHMSA-N 0.000 description 6
- 230000008099 melanin synthesis Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000011590 β-tocopherol Substances 0.000 description 6
- 235000007680 β-tocopherol Nutrition 0.000 description 6
- 102000003425 Tyrosinase Human genes 0.000 description 5
- 108060008724 Tyrosinase Proteins 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000003810 hyperpigmentation Effects 0.000 description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000015782 Electron Transport Complex III Human genes 0.000 description 3
- 108010024882 Electron Transport Complex III Proteins 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- 210000004209 hair Anatomy 0.000 description 3
- -1 hutaquinone Chemical compound 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000002752 melanocyte Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 235000019155 vitamin A Nutrition 0.000 description 3
- 239000011719 vitamin A Substances 0.000 description 3
- 229940045997 vitamin a Drugs 0.000 description 3
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010014970 Ephelides Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 2
- 101710093778 L-dopachrome tautomerase Proteins 0.000 description 2
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 description 2
- 206010040865 Skin hyperpigmentation Diseases 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000002845 discoloration Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 208000000069 hyperpigmentation Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 229940035936 ubiquinone Drugs 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010070835 Skin sensitisation Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000001058 brown pigment Substances 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000005016 dendritic process Effects 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 230000035614 depigmentation Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000012750 in vivo screening Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- CDWVFJJMYKSVHM-HSMQXHTESA-N methyl 5-methoxy-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxymethyl]oxan-2-yl]oxybenzoate Chemical compound COC(=O)C1=CC(OC)=CC=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)CO2)O)O1 CDWVFJJMYKSVHM-HSMQXHTESA-N 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000007886 mutagenicity Effects 0.000 description 1
- 231100000299 mutagenicity Toxicity 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 231100000370 skin sensitisation Toxicity 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 229950011392 sorbitan stearate Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229960004747 ubidecarenone Drugs 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H3/00—Appliances for aiding patients or disabled persons to walk about
- A61H3/04—Wheeled walking aids for patients or disabled persons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/01—Constructive details
- A61H2201/0157—Constructive details portable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/01—Constructive details
- A61H2201/0161—Size reducing arrangements when not in use, for stowing or transport
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2205/00—Devices for specific parts of the body
- A61H2205/10—Leg
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Rehabilitation Therapy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cosmetics (AREA)
Abstract
Description
본 발명은 피부 색소 이상 증상 및 피부 색소 과침착 현상을 개선 또는 방지하는 피부 미백용 화장료 조성물에 관한 것이다. 보다 상세하게는, 코엔자임 Q10(유비퀴논), 베타-카로틴, 토코페롤, 멜로우 추출물 및 프리물라 추출물을 함유함으로써 피부의 멜라닌 생성을 억제하고, 기미, 주근깨, 피부 잡티 및 태양 광선에 의한 피부 그을림 등의 피부 색소 침착 현상을 억제하고 개선하는 효과를 가진 피부 미백용 화장료 조성물에 관한 것이다.The present invention relates to a cosmetic composition for skin whitening that improves or prevents skin pigment abnormalities and skin pigment overdeposition. More specifically, by containing coenzyme Q10 (ubiquinone), beta-carotene, tocopherol, mellow extract and Primula extract to inhibit melanin production of the skin, such as blemishes, freckles, skin blemishes and sunburn skin The present invention relates to a cosmetic composition for skin whitening having an effect of inhibiting and improving skin pigmentation.
사람의 피부색을 결정하는 멜라닌(melanin)은 멜라노사이트(melanocyte)에서 생성되는데, 상기 멜라노사이트에 존재하는 티로시나제 (tyrosinase)등의 효소와 함께 작용하여 생체내에 항상 존재하는 아미노산인 티로신(tyrosine)을 기질로 중합화 산화반응을 함으로써 흑갈색의 색소인 멜라닌을 형성하게 된다. 이렇게 형성된 멜라닌은 멜라노사이트의 수지상 돌기를 통하여 케라티노사이트(keratinocyte)라는 표피 세포로 이동하며, 생체 내에는 멜라닌을 분해하는 효소가 없고 다만 케라티노사이트가 표피에서 떨어져나갈 때 같이 피부에서 떨어져나가는 것으로 제거 된다.Melanin (melanin), which determines the color of human skin, is produced in melanocytes, which work with enzymes such as tyrosinase, which is present in melanocytes, to form tyrosine, an amino acid that is always present in vivo. The polymerization oxidation reaction is carried out to form melanin, which is a dark brown pigment. The melanin thus formed is transferred to the epidermal cells called keratinocytes through the dendritic processes of melanocytes, and there is no enzyme that degrades melanin in the body, but it is separated from the skin as keratinocytes are separated from the epidermis. Is removed.
이렇게 형성된 멜라닌은 핵주변에 모자와 같은 구조를 형성하여 자외선으로부터 유전자를 보호하고 자유 라디칼(free radical)을 제거하여 세포 내 단백질을 보호하는 등 중요한 역할을 하게 된다. 그러나 멜라닌이 필요 이상으로 많이 생기게 되면 기미나 주근깨, 점 등과 같은 과색소침착증을 유발하여 미용상으로 좋지 않은 결과를 가져오게 된다. 또한 레져 인구의 증가로 외부에서 활동하는 것을 즐기는 사람들이 많아지면서 자외선에 의한 멜라닌 색소 침착 현상은 더욱 심화되고 있으며 과색소침착은 피부미용상 관점에서 심각한 정신적 부담을 주어 정상적인 사회활동에 지장을 주기도 한다. 특히 동양권의 여성들은 예로부터 하얗고 고운 피부를 선호해 왔으며, 이를 미의 중요한 기준으로 삼아오면서 피부 색소 이상 증상과 과색소 침착등의 예방과 개선에 대한 욕구가 더욱 늘어나고 있으며, 이에 멜라닌의 과잉생성 예방을 목적으로 하는 미백용 화장품과 약제들의 개발이 활발히 진행되고 있다.The melanin thus formed forms a cap-like structure around the nucleus, and plays an important role such as protecting genes from ultraviolet rays and removing free radicals to protect intracellular proteins. However, if the melanin is produced more than necessary, it causes the hyperpigmentation, such as blemishes, freckles, spots, etc., resulting in cosmetically bad results. In addition, as more people enjoy working outside due to the increase in the leisure population, melanin pigmentation due to ultraviolet rays is intensifying, and hyperpigmentation is a serious mental burden in terms of skin beauty, which can interfere with normal social activities. In particular, women in the Asian region have long favored white and fine skin, and this has become an important criterion of beauty, and the desire for prevention and improvement of abnormal skin pigmentation and hyperpigmentation is increasing, thus preventing overproduction of melanin. The development of cosmetics and drugs for whitening for the purpose is actively progressing.
구체적인 예를 들면 종래로부터 아스코르빈산(ascorbic acid), 하이드로퀴논(hudroquinone), 글루타치온(glutathione), 알부틴(arbutin) 등의 티로시나제 저해활성을 가진 물질들이 화장료나 의약품에 배합하여 사용되어 왔으나, 이들중 대부분의 것은 효과가 불충분하거나 제형상 불안정한 면이 있고, 하이드로퀴논 같은 화합물은 강한 탈색작용을 나타내지만 자체가 피부감작성을 가지고 있어 피부알레르기 등을 유발할 수 있고, 정상적인 피부의 기능을 변화시켜 백반증을 유발하는 등, 피부에 대한 안전성 측면에서 그 사용이 제한되고 있다.For example, conventionally, substances having tyrosinase inhibitory activities such as ascorbic acid, hydroquinone, hutaquinone, glutathione, arbutin, and the like have been used in cosmetics or pharmaceuticals, but among them, Most of them are ineffective or unstable in formulation. Hydroquinone-like compounds show strong depigmentation, but they have skin sensitization, which can cause skin allergies and change the function of normal skin. Its use is limited in terms of safety to the skin.
이에, 본 발명자들은 피부 미백효과가 우수하면서 제형내 불안정성, 피부 자극성, 감작성, 변이원성 등이 없는 화장료 개발을 위해 연구를 거듭한 결과, 대표적 항산화제인 코엔자임 Q10, 베타-카로틴 및 토코페롤에 멜로우 추출물 및 프리물라 추출물의 유효성분을 더 함유함으로써 피부 색소 이상 증상 및 피부 색소 과침착 현상을 개선 또는 방지하는 미백효과가 우수한 화장료 조성물을 발견하고 본 발명을 완성하였다.Accordingly, the present inventors conducted a study for the development of cosmetics having excellent skin whitening effect and no instability, skin irritation, sensitization, mutagenicity, etc. in the formulation, as a representative extract of mellow extract and coenzyme Q10, beta-carotene and tocopherol By further containing an active ingredient of Primula extract, a cosmetic composition with excellent whitening effect of improving or preventing skin pigment abnormalities and skin pigment overdeposition is completed and the present invention has been completed.
따라서 본 발명의 목적은 코엔자임 Q10, 베타-카로틴, 토코페롤, 멜로우 추출물 및 프리물라 추출물을 함유하는 피부 미백용 화장료 조성물을 제공하는 것이다.Accordingly, it is an object of the present invention to provide a cosmetic composition for skin whitening containing coenzyme Q10, beta-carotene, tocopherol, mellow extract and primula extract.
상기한 목적을 달성하기 위하여, 본 발명의 피부 미백용 화장료 조성물은 코엔자임 Q10, 베타-카로틴, 토코페롤, 멜로우(당아욱, 속명 : Malva Sylvestris) 추출물 및 프리물라(앵초, 속명 : Primula Veris) 추출물을 함유하는 것을 특징으로 한다.In order to achieve the above object, the cosmetic composition for skin whitening of the present invention contains coenzyme Q10, beta-carotene, tocopherol, mellow (mallow, genus: Malva Sylvestris ) extract and Primula (primrose, genus: Primula Veris ) extract Characterized in that.
또한 상기 코엔자임 Q10, 베타-카로틴, 토코페롤, 멜로우 추출물 및 프리물라 추출물의 각 함량은 조성물 총 중량에 대하여 각각 0.001~20 중량%인 것을 특징으로 한다.In addition, the content of the coenzyme Q10, beta-carotene, tocopherol, mellow extract and Primula extract is characterized in that each of 0.001 ~ 20% by weight relative to the total weight of the composition.
이하, 본 발명을 보다 상세히 설명한다.Hereinafter, the present invention will be described in more detail.
본 발명에 사용하는 코엔자임 Q10은 유비퀴논(ubiquinone), 유비데카레논(ubidecarenone)등으로도 불리며 인체 세포 내에 실제 존재하여 에너지 대사의 주요한 조효소로 작용한다. 또한, 코엔자임 Q10은 활성산소(reactive oxygen species)로부터 매개되어 유발되는 자외선에 의한 피부 손상, 피부암, 광노화 또는 피부 색소 이상을 막아주는 강력한 항산화제로 사용되며 피부 멜라닌 형성을 억제하여 피부 색소 이상이나 과색소 침착을 개선하는 효과가 있다. 이러한 코엔자임 Q10의 바람직한 함량은 조성물 총 중량에 대하여 0.001~20 중량%이며, 이는 0.001 중량% 미만에서는 피부에 대한 미백효과가 미약하고 20 중량% 초과하면 제형 안정화 등의 면에서 화장료로 적합하지 않기 때문이다.Coenzyme Q10 used in the present invention is also called ubiquinone, ubidecarenone, and the like and is actually present in human cells to act as a major coenzyme of energy metabolism. In addition, Coenzyme Q10 is a powerful antioxidant that prevents skin damage, skin cancer, photoaging or skin pigmentation caused by ultraviolet rays mediated by reactive oxygen species.It is used to inhibit skin pigmentation and hyperpigmentation by inhibiting melanin formation. It has the effect of improving deposition. The preferred content of such coenzyme Q10 is 0.001 to 20% by weight based on the total weight of the composition, because less than 0.001% by weight of the whitening effect on the skin is weak, and more than 20% by weight is not suitable for cosmetics, such as formulation stabilization. to be.
또한 본 발명에 사용하는 베타 카로틴 및 토코페롤은 대표적인 비타민 성분으로 베타 카로틴은 녹황색 야채에 많이 함유되어 있는 색소인 카로테노이드의 일종이며, 체내에서 비타민 A로 변환되어 비타민A의 전구체의 성질을 갖고 있다. 베타 카로틴은 강한 항산화 작용이 있고, 정상세포를 활성산소의 위해로부터 보호하고 피부 세포를 활발하게 해준다. 재생 효과가 있는 베타 카로틴은 그 자체로는 많은 역할을 하지는 않지만 비타민 A의 체내 합성을 도와 신진대사를 원활하게 하는 기능이 있다. 또한 자외선과 공해로 손상된 피부를 치유하는 기능이 있으며, 강한 여름 햇볕을 받는 피부 세포들을 활발하게 도와 피부를 보호하는 기능 및 미백 기능이 있다. In addition, beta carotene and tocopherol used in the present invention is a representative vitamin component beta carotene is a kind of carotenoids, a pigment contained in a lot of green and yellow vegetables, and converted into vitamin A in the body has the properties of a precursor of vitamin A. Beta carotene has a strong antioxidant action, protects normal cells from harmful oxygen free radicals and activates skin cells. Beta-carotene, which has a regenerative effect, does not play a large role in itself, but it has the ability to help metabolize vitamin A in the body. In addition, it has the function of healing the skin damaged by UV rays and pollution, and also has the function of protecting the skin and whitening function by actively helping skin cells subjected to strong summer sun.
또한, 상기 토코페롤은 비타민 E로 불리는 강력한 항산화제로 오래전부터 화 장품이나 식품등에 광범위하게 사용되고 있는 원료이다. 항산화 비타민의 멜라닌 합성조해 기능에 관한 연구에 의하면 β형 토코페롤 및 r형토코페롤은 세포내 치로시나제 활성의 직접 조해효과와 티로시나제 및 TRP-2의 전사 레벨에서의 조해활성에 의해 비교적 강한 멜라닌 합성조해활성이 있는 것이 발견되었다. 또한 δ형 토코페롤은 티로시나제 활성조해가 있는 것이 발견되었으며, 그 메커니즘에 관해서는 TRP-2의 mRNA 합성조해를 하고 있으며, 티로시나제의 mRNA 합성에는 영향이 보이지 않는다고 보고되고 있다.In addition, the tocopherol is a powerful antioxidant called vitamin E, and has been widely used in cosmetics and food for a long time. Studies on the Melanin Synthesis-Assisting Function of Antioxidant Vitamins According to the study, β-type tocopherol and r-type tocopherol have relatively strong melanin synthesis due to the direct detoxification effect of intracellular chirosinase activity and the detoxification activity at the transcription level of tyrosinase and TRP-2. It was found to have deliquescent activity. In addition, δ-type tocopherol has been found to have tyrosinase activator, and the mechanism of TRP-2 mRNA synthesis has been reported, and it has been reported that there is no effect on tyrosinase mRNA synthesis.
항산화제인 베타 카로틴 및 토코페롤의 함량은 조성물 총 중량에 대하여 각각 0.001~20 중량%인 것이 바람직하다. 각 성분의 함량이 0.001중량% 미만인 경우에는 피부에 대한 효과가 미약하여 미백효과를 기대하기 어려우며, 20중량% 초과인 경우에는 변색, 변취의 문제 뿐만 아니라 피부 자극의 우려가 있어 화장료로 적합하지 않다.The content of the antioxidant beta carotene and tocopherol is preferably 0.001 to 20% by weight based on the total weight of the composition. If the content of each component is less than 0.001% by weight, it is difficult to expect a whitening effect due to the slight effect on the skin, and when it is more than 20% by weight, it is not suitable as a cosmetic because it may cause discoloration and odor, as well as skin irritation. .
본 발명에 사용하는 멜로우(당아욱, 속명 : Malva Sylvestris)는 옛날부터 여러 용도로 이용될 정도로 역사가 오랜된 허브이다. 고대 아라비아에서는 염증을 없애는 데에 사용했다. 프리물라(앵초, 속명 : Primula Veris)는 대표적인 허브 식물로 다년생 초본식물인 앵초로써 유럽사회에서는 오래 전부터 약용으로 이용되고 있다. 우리나라에서도 진해, 거담, 해소, 기관지염등에 사용되고 있으며 다량의 사포닌을 포함하고 있다.Mellow (mallow, genus: Malva Sylvestris ) used in the present invention is a herb that is old enough to be used for various purposes since ancient times. In ancient Arabia, it was used to eliminate inflammation. Primula Veris is a herbaceous herb that is a perennial herbaceous plant and has been used for many years in the European community. It is used in Jinhae, expectorant, relieving and bronchitis in Korea and contains a large amount of saponin.
또한, 멜로우는 가수 분해 가능한 점액질 아라비노즈, 글루코즈, 람노오즈, 갈락토오즈 갈락투로닉 산 및 탄닌류의 화합물을 함유하고 있으며 호흡기 계열의 치료제로도 널리 사용되고 있는 식물이고, 프리물라는 주요 성분으로 5~10%의 사포닌, 페놀릭 글루코사이드 및 프리물라베린을 함유하고 있으며 적은 양의 슈가 및 탄닌 성분을 함유 하고 있는 식물이다.Mellow also contains compounds of hydrolyzable mucus arabinose, glucose, rhamnose, galactose galacturonic acid and tannins, and is widely used as a respiratory therapeutic agent. This plant contains 5-10% saponin, phenolic glucoside and primulaverin and contains a small amount of sugar and tannin.
본 발명에서 미백을 위해 사용하는 멜로우 추출물 및 프리물라 추출물의 바람직한 함량은 조성물 총 중량에 대하여 각각 0.001~20 중량%이며, 각 성분의 함량이 0.001중량% 미만인 경우에는 피부에 대한 효과가 미약하고, 20중량% 초과인 경우에는 변색, 변취의 문제 뿐만 아니라 제형 내 침전 발생 여부 등의 이유로 화장료로 적합하지 않다.In the present invention, the preferred content of the mellow extract and Primula extract used for whitening is 0.001 to 20% by weight based on the total weight of the composition, and when the content of each component is less than 0.001% by weight, the effect on the skin is weak, If it is more than 20% by weight, it is not suitable as a cosmetic for reasons such as discoloration and deodorization as well as occurrence of precipitation in the formulation.
본 발명의 멜로우 추출물은 Malva Sylvestris의 잎, 줄기, 뿌리에서 추출한 성분이다.Mellow extract of the present invention is a component extracted from the leaves, stems, roots of Malva Sylvestris .
또한 본 발명의 프리물라는 Primula Veris의 잎, 줄기, 뿌리에서 추출한 성분이다. 멜로우와 프리물라의 추출물은 통상의 식물 추출 방법인 증류법, 용매 추출법 등을 이용하여 추출하여 수득할 수 있다. In addition, Primula of the present invention is a component extracted from the leaves, stems, roots of Primula Veris . Mellow and Primula extracts can be obtained by extracting using conventional plant extraction methods such as distillation, solvent extraction, and the like.
본 발명의 화장료 조성물은 그 제형에 있어서 특별히 한정되는 바가 없으며, 예를 들면 유연화장수, 영양화장수, 마사지크림, 영양크림, 에센스,팩, 젤 또는 피부 점착 타입 화장료의 제형을 갖는 화장료 조성물일 수 있다.The cosmetic composition of the present invention is not particularly limited in its formulation, and may be, for example, a cosmetic composition having a formulation of a flexible cosmetic water, nourishing cosmetic water, massage cream, nutrition cream, essence, pack, gel or skin adhesive type cosmetic. .
이하, 실시예 및 시험예를 들어 본 발명을 보다 구체적으로 설명하지만, 본 발명의 범위가 반드시 이들 예로만 한정되는 것은 아니다.Hereinafter, although an Example and a test example are given and this invention is demonstrated more concretely, the scope of the present invention is not necessarily limited only to these examples.
[시험예 1: 멜라닌 생성억제 효과 측정]Test Example 1: Measurement of melanin production inhibitory effect
인간 멜라노마 세포인 HM3KO 세포(Y. Funasaka, Department of dermatology, Kobe university school of medicine, 5-1 Kusunoki-cho 7-chrome, Chuo-ku, Kobe 650, Japan)를 우태아혈청이 10% 들어간 Minimum Essential Medium(MEM)에 넣어 37℃, 5% CO2 조건하에서 배양하였다. 이렇게 배양한 세포를 세포수가 각 플라스크 당 3 ×105이 되게 75 플라스크에 깔고, 하룻밤 동안 세포가 기벽에 붙기를 기다린 다음 세포가 잘 붙은 것을 확인한 후, 배지를 하기 표 1의 조성으로 제조한 WQP complex Ⅰ, Ⅱ 및 Ⅲ의 시험물질이 10ppm 들어 있는 새 배지로 갈아주었다. 대조구는 DMSO가 들어 있는 배지를 사용하였다. 이와 같은 방법으로 2~3일에 한번씩 시료가 들어 있는 새 배지로 갈아주면서 세포가 플라스크에 꽉 찰 때까지 배양하였다. 세포가 다 성장하면 모아서 대조구와 각각 처리구의 세포 색깔을 비교하여 그 결과를 하기 표 1에 나타내었다. 또한, 배양액을 제거하고 PBS로 세척한 후 1N 수산화나트륨으로 녹여 500㎚에서 흡광도를 측정한 후 하기 수학식1에 따라 멜라닌 생성 억제율을 계산하여 그 결과를 하기 표 1에 나타내었다.Minimum HM3KO cells (Y. Funasaka, Department of dermatology, Kobe university school of medicine, 5-1 Kusunoki-cho 7-chrome, Chuo-ku, Kobe 650, Japan), human melanoma cells Incubated in Essential Medium (MEM) at 37 ℃, 5% CO 2 conditions. The cultured cells were spread in 75 flasks so that the number of cells was 3 × 10 5 per flask, and the cells were allowed to adhere to the wall for one night. After confirming that the cells adhered well, the medium was prepared with the composition of Table 1 below. The fresh medium containing 10 ppm of the test substance of complex I, II and III was changed. As a control, a medium containing DMSO was used. In this manner, the cells were incubated with a new medium containing the sample every two to three days, until the cells were filled in the flask. When the cells are grown, the cells of the control and the control groups are compared and the results are shown in Table 1 below. In addition, the culture medium was removed, washed with PBS, dissolved with 1N sodium hydroxide, and measured for absorbance at 500 nm, and then the melanin production inhibition rate was calculated according to Equation 1 shown in Table 1 below.
* 코엔자임 Q10 (일본 NISSHIN PHARMA)* Coenzyme Q10 (NISSHIN PHARMA, Japan)
** 베타카로틴 (Colletica, 프랑스)** Beta-carotene (Colletica, France)
*** 토코페놀 (Colletica, 프랑스)*** Tocophenol (Colletica, France)
**** 멜로우 추출물(Pentapharm, 스위스)**** Mellow Extract (Pentapharm, Switzerland)
***** 프리물라 추출물(Pentapharm, 스위스)***** Primula Extract (Pentapharm, Switzerland)
상기 표 1의 결과로부터 각 시료를 개별로 사용하였을 경우보다 WQP 복합체 Ⅰ, Ⅱ를 이루어 사용한 경우가 우수한 미백효과를 나타냈고 그 중 WQP 복합체 Ⅲ, 즉 미백 유효 성분을 모두 함께 사용한 경우가 가장 좋은 미백 효과를 보인다는 결론을 얻었다.From the results of Table 1, the whitening effect of the WQP complexes I and II was superior to that of each sample individually, and the best whitening of the WQP complex III, that is, the whitening active ingredient, was used together. The effect was concluded.
[시험예 2: 동물수준에서의 미백 효과 평가] [Test Example 2: Evaluation of the whitening effect at the animal level]
갈색 몰모트(Tortoiseshell guinea pigs; Brown guinea pigs)는 사람과 같이 자외선, PUVA, 알레르기 반응 등에 의해 색소침착이 생기는 동물로, 털과 피부의 빛깔이 동일하기 때문에 털의 빛깔이 균일하고 갈색인 것을 고르면 털을 제거한 뒤에 광범위한 부위를 사용할 수 있다. 하기에 열거한 방법으로 색소침착을 생기게 하고, 그 색소침착 부위에 미백 조성물을 도포하는 방법에 의해 색소침착의 개선효과를 검증하였다. 또한, 이러한 방법으로 효과가 인정된 물질은 사람의 자외선 색소반에서의 평가에도 효과가 나타날 확률이 높기 때문에 일차 생체 내 검색법으로 유용하게 사용된다.Brown guinea pigs (Tortoiseshell guinea pigs) are animals that cause pigmentation due to ultraviolet rays, PUVA, and allergic reactions, such as humans.As the color of the hair is the same, the color of the hair is uniform and brown. After removal, a wide range of sites can be used. Pigmentation was produced by the method listed below, and the improvement effect of pigmentation was verified by the method of apply | coating the whitening composition to the pigmentation site | part. In addition, the substances whose effects have been recognized in this way are useful as primary in vivo screening methods because they have a high probability of being effective in evaluation in human UV pigment plaques.
① 자외선 색소반의 제작법① Preparation of UV Pigment
자외선(UVB)에 의한 색소침착의 제작은 갈색 몰모트 배후의 털을 제거한 피부에 3×3cm의 정방형의 창문이 6개 뚫린 차광용 알루미늄 호일을 접착시킨 후, SE 램프(파장 290∼320nm, Toshiba)로 자외선(UVB)을 조사하였다(총조사 에너지량은 1350mJ/cm2). 조사 후 알루미늄 호일을 벗겨내고 하기와 같은 도포방법으로 시험물질의 미백효과를 평가하였다. 자외선 조사 후 색소침착은 2~3일 뒤에 나타나며, 약 2주 후에 최고에 달한다. 이때, 생성된 자외선 색소반의 색조가 동일하며 얼룩이 생기지 않는 것이 중요하며 자외선 색소반의 형성이 좋지 않은 개체는 좋은 결과를 위해 쓰지 않는 편이 좋다.Pigmentation by ultraviolet (UVB) was carried out by bonding a light-shielding aluminum foil having six square windows of 3 × 3 cm to the skin from which the hairs behind the brown malmot were removed, followed by an SE lamp (wavelength 290-320 nm, Toshiba). Ultraviolet (UVB) was irradiated with (the total irradiation energy amount was 1350mJ / cm 2 ). After irradiation, the aluminum foil was peeled off and the whitening effect of the test substance was evaluated by the following coating method. Pigmentation after UV irradiation appears 2-3 days later, reaching peak after about 2 weeks. At this time, it is important that the generated color tone of the ultraviolet dye spot is the same and does not cause staining, and an object having poor formation of the ultraviolet dye spot is not used for good results.
② 조성물의 도포방법② Application of Composition
자외선 조사 후 하기 표 2의 조성물은 색소침착이 최고가 되는, 즉 색소침착이 형성된지 약 14일 뒤에 도포하기 시작하였다. 도포회수는 l일 1회 또는 2회로 50일간 계속하였다. 조성물은 프로필렌글리콜:에탄올:물=5:3:2의 혼합용매에 용해 및 희석되었으며 면봉으로 도포하고, 반드시 다른 부위에 용매를 도포하는 대조부위를 마련하였다. 효과 판정과 함께 누적자극성 여부도 관찰하였다.After ultraviolet irradiation, the composition of Table 2 began to be applied about 14 days after the pigmentation was the highest, that is, the pigmentation was formed. The application number of times was continued for 50 days once or twice a day. The composition was dissolved and diluted in a mixed solvent of propylene glycol: ethanol: water = 5: 3: 2 and applied with a cotton swab to prepare a control site for necessarily applying a solvent to other sites. Along with the determination of effects, the cumulative stimulus was also observed.
③ 효과의 판정 ③ judgment of effect
색차계(미놀타 CR2002)를 사용하여 피부의 흑백정도를 측정하여 효과를 판정하였다. 색을 표시하는 데에는 L*a*b* 표색계를 사용하며, 본 발명에서는 주로 L* 값(명도)을 지표로 하였다. L* 값은 표준 백판으로 교정하며, 측정은 1개 부위에 5회 이상 측정을 되풀이함으로써 색소침착부를 균등하게 측정하였다. 도포 시작시점과 완료시점에서의 피부색의 차이(△L*)를 하기 수학식 2에 따라 계산하고, 이를 표 3에 나타내었다. 미백효과는 시료 도포 부위와 대조군 부위의 △L*의 비교로 판정하는데, △L*값이 2정도일 경우는 침착된 색소의 미백화가 뚜렷한 경우이고, 1.5정도 이상이면 미백효과가 있다고 판정하였다.The effect was determined by measuring the degree of black and white of the skin using a color difference meter (Minolta CR2002). L * a * b * colorimeter is used for displaying a color, and in this invention, L * value (brightness) was mainly used as an index. The L * value was calibrated with a standard whiteboard, and the pigmentation part was measured evenly by repeating the measurement five times or more at one site. The difference in skin color (ΔL *) at the start and completion of the application was calculated according to Equation 2 below, which is shown in Table 3. The whitening effect was determined by comparing ΔL * between the sample application site and the control site. When the ΔL * value was about 2, the whitening effect of the deposited pigment was apparent, and when it was about 1.5 or more, the whitening effect was determined.
표 3의 결과로부터, 본 발명의 조성물은 1.0%의 농도에서 침착된 색소의 미백화가 뚜렷하고 0.1%의 농도에서도 미백효과를 나타냄을 알 수 있으며, 코지산의 경우는 실험동물의 붉은 기의 색소가 침착되어 오히려 효과가 반감되는 결과를 가져옴을 알 수 있었다.From the results of Table 3, the composition of the present invention can be seen that the whitening of the pigment deposited at a concentration of 1.0% is clear and exhibits a whitening effect even at a concentration of 0.1%. It was found that the deposition resulted in the effect being halved.
[실시예 1~3 및 비교예 1~6][Examples 1-3 and Comparative Examples 1-6]
인체 피부에 대한 미백효과를 실험하기 위해 하기 표 4의 원료 1-6과 10,11을 혼합하여 70℃에서 용해하여 물파트로 하였다. 한편, 원료 7-9, 12-19를 70℃에서 용해하여 오일파트로 하였다. 오일파트를 물파트에 첨가하고 호모믹서(일본 Tokushu Kika 社)로 교반하여 1차 유화하고, 원료 20을 첨가하여 점증하였다. 기포를 제거한 후, 실온으로 냉각시켜 실시예 1~3 및 비교예 1~6로 사용하였다.In order to test the whitening effect on the human skin, raw materials 1-6 and 10,11 shown in Table 4 were mixed, dissolved at 70 ° C., and used as water parts. In addition, raw materials 7-9 and 12-19 were melt | dissolved at 70 degreeC, and it was set as the oil part. The oil part was added to the water part, stirred with a homomixer (Tokushu Kika Co., Ltd., Japan), and first emulsified. After removing bubbles, the mixture was cooled to room temperature and used in Examples 1-3 and Comparative Examples 1-6.
[시험예 3: 인체 피부에 대한 미백 효과 시험][Test Example 3: Whitening effect test on the human skin]
건강한 12명의 남자를 대상으로 피검자의 윗팔뚝 부위에 직경 1.5cm의 구멍 6개가 뚫린 불투명 테이프를 부착한 뒤, 각 피검자의 최소 홍반량(Minimal Erythema Dose)의 1.5~2 배 정도의 자외선(UVB)을 조사하여 피부의 흑화를 유도하고, 시험물질들을 도포하여 두 달 후에 색차계를 이용하여 피부의 명암을 측정하였다. 각 시험물질들은 실시예 1~3 및 비교예 1~6의 피부 외용제를 아침, 저녁 2회씩 매일 바르게 하였다.Twelve healthy men were attached with an opaque tape with six 1.5cm diameter holes in the upper forearm of the subject, and 1.5 ~ 2 times the UVB of the minimum Erythema Dose of each subject. The blackening of the skin was induced by irradiating and the test materials were applied and two months later, the contrast of the skin was measured using a color difference meter. Each test substance was applied to the skin external preparations of Examples 1 to 3 and Comparative Examples 1 to 6 twice daily in the morning and evening.
효과의 판정은 동물시험에서와 마찬가지로 피부의 명암을 나타내는 "L"값을 구하여 결정하였다(태우지 않은 한국인 피부색은 일반적으로 50-70의 값을 나타냄).Judgment of the effect was determined by obtaining an "L" value representing the skin's contrast as in animal testing (unburned Korean skin color generally ranges from 50-70).
시험물질을 도포하여 효과가 있는 경우는 L값이 점차 증가하게 되며 시험물질들 사이의 비교는 도포 시작시점과 완료시점에서의 피부색의 차이(△L)를 하기 수학식 2에 따라 계산하고, 이를 표 5에 나타내었다.When the test substance is effective, the L value is gradually increased, and the comparison between the test substances is calculated according to the following equation (2) of the difference in skin color (ΔL) between the start point and the end point of the application. Table 5 shows.
위 표 5에서 알 수 있듯이, 코엔자임 Q10, 베타-카로틴, 토코페롤, 멜로우 추출물 및 프리물라 추출물을 각각 단독으로 사용한 경우보다, 코엔자임 Q10, 베타카로틴, 토코페롤을 함께 사용한 경우와 코엔자임 Q10, 멜로우 추출물 및 프리물라 추출물을 함께 사용한 것과 같은 혼합물 조성에서 미백 효과가 좀 더 높은 것으로 나타났으며, 그 중 다섯 가지 미백 효능 물질인 코엔자임 Q10, 베타-카로틴, 토코페롤, 멜로우 추출물 및 프리물라 추출물을 모두 함께 사용한 경우가 미백 효과에 있어 가장 좋은 효과를 나타내었다. 상기 결과를 바탕으로 미백 조성물에 있어 위 원료들이 시너지 효과가 있음을 알 수 있었다.As can be seen in Table 5 above, coenzyme Q10, beta-carotene, tocopherol and coenzyme Q10, beta-carotene, tocopherol extract and coenzyme Q10, beta-carotene, tocopherol, and coenzyme Q10, mellow extract and free The whitening effect was found to be higher in the same composition as the Mulla extract, and all of the five whitening agents, coenzyme Q10, beta-carotene, tocopherol, mellow extract and Primula extract, were used together. It showed the best effect on the whitening effect. Based on the results, it was found that the above raw materials have a synergistic effect in the whitening composition.
이상에서 설명한 바와 같이, 본 발명에 의하여 제공되는 화장료 조성물은 대 표적 항산화 물질인 코엔자임 Q10, 베타카로틴 및 토코페롤과 허브 식물 추출물인 멜로우 추출물 및 프라물라 추출물을 함께 사용함으로써 피부에 안전하고 제형내에서 안정하며 미백 효과가 뛰어난 미백용 화장료 조성물로 사용될 수 있다.As described above, the cosmetic composition provided by the present invention is safe to the skin and is stable in the formulation by using coenzyme Q10, beta-carotene and tocopherol and the herbal plant extract mellow extract and pramula extract, which are the target antioxidants And it can be used as a cosmetic composition for whitening excellent whitening effect.
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060010013A KR20070079390A (en) | 2006-02-02 | 2006-02-02 | Cosmetic composition for skin whitening |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060010013A KR20070079390A (en) | 2006-02-02 | 2006-02-02 | Cosmetic composition for skin whitening |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20070079390A true KR20070079390A (en) | 2007-08-07 |
Family
ID=38600005
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020060010013A KR20070079390A (en) | 2006-02-02 | 2006-02-02 | Cosmetic composition for skin whitening |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20070079390A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012055580A3 (en) * | 2010-10-28 | 2013-02-07 | Henkel Ag & Co. Kgaa | Use of purine and/or a purine derivative and at least one biochinone for influencing the natural pigmentation process |
CN104323931A (en) * | 2013-07-22 | 2015-02-04 | 强生消费者公司 | Methods of treating a skin condition with malva neglecta |
-
2006
- 2006-02-02 KR KR1020060010013A patent/KR20070079390A/en not_active Application Discontinuation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012055580A3 (en) * | 2010-10-28 | 2013-02-07 | Henkel Ag & Co. Kgaa | Use of purine and/or a purine derivative and at least one biochinone for influencing the natural pigmentation process |
CN104323931A (en) * | 2013-07-22 | 2015-02-04 | 强生消费者公司 | Methods of treating a skin condition with malva neglecta |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100825450B1 (en) | Skin anti-wrinkle cosmetics composition containing Forsythiae Fruit extract | |
KR101809266B1 (en) | Cosmetic composition containing propolis complex extracts | |
US9079047B2 (en) | Cosmetic composition for skin whitening | |
KR101824770B1 (en) | Anti-wrinkle cosmetic composition comprising essentially Polygonum multiflorum adventitious extract | |
KR101716489B1 (en) | Cosmetic composition containing sageretia theezans extracts | |
KR100521768B1 (en) | Cosmetic Compositions for a Skin Whitening | |
KR101299024B1 (en) | Cosmetics composition for skin lightening color, antioxidantsand and method for preparing the same | |
KR100959393B1 (en) | Skin whitening cosmetics composition containing an effective ingredient extracted from Acanthopanax sessiliflorum Seeman and manufacturing method thereof | |
KR100795514B1 (en) | Composition for skin whitening containing diosgenin | |
KR100371504B1 (en) | Cosmetics composition comprising extract powder with vitis vinifera l.fermented solution and having whitening and anti-wrinkle effect | |
KR20070079390A (en) | Cosmetic composition for skin whitening | |
KR101093901B1 (en) | A cosmetic composition comprising an extract of tissue cultured anoectochilus formosanus and a preparation method of the extract of tissue cultured anoectochilus formosanus | |
KR20010060882A (en) | A composition for external application for skin whitening | |
KR100883773B1 (en) | Cosmetic compositions comprising fermenting extracts of citrus junos fruit or poncirus trifoliata fruit with salt | |
KR101686521B1 (en) | Composition for beauty of skin | |
KR20050092313A (en) | Skin whitening cosmetic containing a herb extract with inhibitory activity of melanin formation | |
KR101317433B1 (en) | The cosmetic composition for skin whitening comprising the mixture of extract of Hovenia dulcia, Platycodon grandiflorum, wheat bud and sage | |
KR20110043019A (en) | Composition for skin whitening consist of plant exract and cosmetic compostion comprising the plant extract compostion | |
KR101161738B1 (en) | Composition for skin whitening containing ginsenoside Rh2 | |
KR20080111299A (en) | Whitening composition for external applications to the skin containing premature kaempferol-3,7-o-alpha-l-dirhamnopyranoside | |
KR20130089559A (en) | Anti-aging composition | |
KR100965085B1 (en) | Composition for cosmetic application having skin whitening function | |
KR100821482B1 (en) | External skin application composition for skin whitening | |
KR102160306B1 (en) | skin whitening agent | |
KR100901519B1 (en) | Agents for skin whitening containing platycodin d |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
N231 | Notification of change of applicant | ||
A201 | Request for examination | ||
E601 | Decision to refuse application |